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Running title: Diabetes service delivery and COVID-19 
 
This manuscript is part of a commissioned series of urgent clinical guidance documents on 
the management of endocrine conditions in the time of Coronavirus Disease 19 (COVID-19).  
This clinical guidance document underwent expedited open peer review by reviewer 1 
(centre), reviewer 2 (centre), reviewer 3 (centre), reviewer 4 (centre) 
 
Disclaimer: Due to the emerging nature of the COVID-19 crisis this document is not based 
on extensive systematic review or meta-analysis, but on rapid expert consensus. The 
document should be considered as guidance only; it is not intended to determine an 
absolute standard of medical care. Healthcare staff need to consider individual 
circumstances when devising the management plan for a specific patient. 
Abstract 
 
The COVID-19 pandemic is a major international emergency leading to unprecedented 
medical, economic and societal challenges. Countries around the globe are facing challenges 
with diabetes care and are similarly adapting care delivery, with local cultural nuances.  
People with diabetes suffer disproportionately from acute COVID-19 with higher rates of 
serious complications and death. In-patient services need specialist support to appropriately 
manage glycaemia in people with known and undiagnosed diabetes presenting with COVID-
19. Due to the restrictions imposed by the pandemic, people with diabetes may suffer 
longer-term harm caused by inadequate clinical support and less frequent monitoring of 
their condition and diabetes-related complications. Outpatient management need to be 
reorganised to maintain remote advice and support services, focusing on proactive care for 
the highest risk, and using telehealth and digital services for consultations, self-
management and remote monitoring, where appropriate. Stratification of patients for face-
to-face or remote follow-up should be based on a balanced risk assessment.  Public health 
and national organisations have generally responded rapidly with guidance on care 
management, but the pandemic has created a tension around prioritisation of 
communicable vs non-communicable disease. Resulting challenges in clinical decision 
making are compounded by a reduced clinical workforce.  For many years, increasing 
diabetes mellitus incidence has been mirrored by rising preventable morbidity and mortality 
due to complications, yet innovation in service delivery has been slow.  While the current 
focus is on limiting the terrible harm caused by the pandemic, it is possible that a positive 




This publication was created through collaborative working between UK and International 
diabetes leaders and experts. It represents the situation, as of 12 April 2020, 4 weeks post 
‘lock-down’, at which time 10,621 people have died of COVID-19 in the UK (1) and 99,690 
internationally (2). The current UK Government advice to people with diabetes is to follow 
general public ‘stay at home guidance’. Shielding/ complete self-isolation is not currently 
stipulated for diabetes, unlike very high-risk individuals with severe respiratory illnesses or 
compromised immunity. This advice is largely mirrored internationally. 
 
Diabetes and COVID-19 
COVID-19 has resulted in the biggest disruption to healthcare delivery in living memory. 
New policy and healthcare working practice have been rapidly introduced. This article 
focuses on changes to diabetes care delivery during the pandemic. Currently it is unclear 
whether people with diabetes are at higher risk of contracting COVID-19. However, they are 
clearly at higher risk of poor outcomes once infected. Among 7,162 US cases reported by 
the CDC (28th March), the percentage of COVID-19 patients with at least one underlying 
health condition (e.g diabetes) was nearly 3-fold higher among those requiring i) intensive 
care unit admission (78%) and ii) hospitalisation (71%) compared to people not hospitalised 
(27%) (3,4). People with diabetes may also have a ~2-3 fold increased mortality following 
COVID-19 infection in early reports (4,5). Age, gender, multimorbidity, low socioeconomic 
status, and degree of pathogen exposure are risk factors for disease severity, but it is not 
yet clear which are independent contributors (5,6,7,8,9).   
 
Acute Care for Individual People with Diabetes and COVID-19 
Acute illness suspected or confirmed to be due to COVID-19 may require modification of 
current guidelines, particularly for safe use by staff unfamiliar with diabetes management, 
to prevent hypoglycaemia and severe hyperglycaemia (10). Guidance to emergency/ 
admissions departments should include glucose measurement on all admissions, as a 
significant number of COVID-19 positive patients not previously known to have diabetes 
present with marked hyperglycaemia. Additionally ketones should be checked both in 
everyone with known diabetes, and in those without known diabetes who present with a 
blood glucose above 12mmol/L. Anecdotal reports suggest that unusual presentations of 
diabetic metabolic emergencies including diabetic ketoacidosis (DKA) or mixed DKA and 
Hyperosmolar Hyperglycaemic State (HHS) in type 2 diabetes with the risk of DKA being 
greater in those on SGLT-2 inhibitors. SGLT-2 inhibitors and metformin should therefore be 
stopped in all patients on acute presentation,  given potential association with metabolic 
emergencies and of AKI.  
. Figure 1 gives useful ‘Front Door’ guidance, for individual patients based on experience 
from UK centres (https://www.diabetes.org.uk/resources-s3/public/2020-
04/COvID_Front_Door_v1.0.pdf). Non-COVID-19 related DKA and HHS should be managed 
using standard protocols and additional support implemented to reduce admissions in 
known high risk individuals (see later). 
 
Diabetes-related Population Health Risks during the COVID-19 Pandemic 
In the general population, restrictions on travel and person-to-person contact may lead to 
worsening of risk factors for complications and poorer health outcomes from established 
diabetes, and rising diabetes incidence through: 
Changes in Lifestyle  
 More sedentary behaviour/ less activity  
 Lack of access to healthy foods 
 Lack of face-to-face, peer and professional support for weight loss/ healthy 
lifestyle  
 Reduced carer/ family support for self-management  
 Increased alcohol consumption (11) 
 Deterioration in mental health, due to stress and isolation and reduced wider 
family network/ peer support. 
Reduced Population Complications Screening/ Acute Treatment Changes 
 Failure to monitor renal function appropriately in people with CKD leading to 
avoidable admissions with fluid overload, anaemia or electrolyte disturbance 
 Failure to monitor blood pressure/ other CVD risk factors appropriately 
leading to preventable CVD events 
 Delay in management of diabetes-related foot ulcers/ foot infections and 
sight-threatening retinopathy leading to preventable amputations and blindness. 
 Inappropriate continuation and discontinuation of medications (12)  
 
Role of Diabetes Specialist/ Community Teams during the time of COVID-19 
It is vital to maintain patient safety while accelerating patient flow through the hospital and 
delivering closely managed outpatient services to prevent avoidable admissions and 
readmissions.  Achieving this involves: 
1) Reducing Risk of COVID-19 Infection through clear articulation of evolving 
COVID-19 advice to people with diabetes, enabling an understand of risk status and 
expectations around healthcare service interaction 
2) Preventing people with diabetes in the community falling ill from diabetes-
related complications (hypoglycaemia, diabetic ketoacidosis (DKA), hyperosmolar 
hyperglycaemic state (HHS), foot infections) 
3) Assisting people with diabetes out of hospital when they become unwell to 
prevent admission for diabetes-related complications  (as above) 
4) Supporting inpatient teams (especially on COVID wards) to manage people 
with acute diabetes complications safely, including those on ICU with high insulin 
requirements 
5) Providing education for front-line inpatient teams who are unfamiliar with 
diabetes management  
6) Facilitating early discharge to the community with programmed daily 
diabetes follow up to prevent readmission  
7) Supporting Primary Care diabetes management 
It is critical to maintain a skeleton service capable of delivering 1, 2, 3 and 6 to keep people 
with diabetes out of hospital, as well as a more significant service for diabetes care in 
hospital. This should ideally include a limited inpatient/ community weekend service. 
 
Practical Advice for Ongoing Out-Patient Management 
Challenges of outpatient care delivery are compounded by reduced staffing levels due to 
illness and deployment of clinicians to “frontline” duties. Smaller numbers of staff are thus 
manning skeleton outpatient services.  The duration of outpatient service disruption is 
currently uncertain. 
 
i) Short Term Service Interruption Guidance (e.g. 1-3 months) 
Suggestions: 
 Face to face clinic review should only occur where health benefits of 
attendance outweigh the risks associated with patient movement (i.e. potential 
individual and wider societal COVID-19 spread). 
 Pregnancy, foot services, and management of newly diagnosed people with 
Type 1 diabetes may need to continue at full capacity, as per national guidance 
(13). 
 Delay routine screening tests unless the patient is at very high risk of 
deterioration e.g. due to age, trajectory of previous test results or past history.  
 Accept that numbers achieving routine care processes (e.g. BP, lipid, HbA1C, 
renal function, ACR, feet and eye screening (14)) will reduce. 
 Continue to advocate national/ personal targets for metabolic parameters, 
using remote monitoring where possible. 
 Aim for complications prevention through a focus on highest risk 
populations. 
 Become familiar with and signpost patients to credible online sources of 
advice, education/ self-management and remote monitoring tools.  
 Pool resources across regions to resource diabetes care services optimally  
 If staff resource depletes due to illness/ reallocation to COVID-19 duties, then 
focus on supporting highest risk patients only, 
 Implement and publicise a telephone/ online advice service 
 
Figure 2 (15) contains a suggested outpatient prioritisation flow chart. 
 
ii) Medium to Longer Term Service Interruption (e.g. 3-12 months) 
As normal service interruption lengthens, the risk of harm due to delayed screening that 
could have informed early intervention and complication avoidance increases. It may 
become necessary to enable routine diabetes screening, using facilities and procedures that 
minimise COVID-19 transmission risk.  Patients at highest risk of deterioration should be 
prioritised using risk algorithms if possible.   
 
Risk Assessment in Care Delivery 
Whilst some IT-integrated risk assessment tools are available (e.g. Eclipse; 
https://www.prescribingservices.org), they have not been adapted for risk assessment 
around routine care delivery during COVID-19, which is generally being done intuitively.  
More advanced data-driven machine learning models could support decisions. Models 
already exist for prediction of i) mortality (16), ii) glycaemic control deterioration, iii) DKA 
(17), iv) eye disease (18,19,20), v) foot ulcers/amputations, vi) kidney failure (20) and vii) 
cardiovascular complications (20). Most models however remain within academic papers 
and few are linked to front-line user interfaces supporting real-time care prioritisation (21). 
In addition, previously developed models were trained in data drawn from contexts where 
populations studied were largely attending regular, scheduled clinical review/ screening 
visits. The current pandemic has driven an unprecedented degree of routine clinical review 
deferral. An excess all-cause mortality in weeks 12 and 13 of 2020 has been observed when 
compared with the same weeks in 5 years to 2019, which is not fully attributable to COVID-
19 (22) suggesting that COVID-19 may be impacting healthcare system performance. 
Machine learning models predicting individual risk of adverse outcomes due explicitly to 
COVID-19 service disruption could prove useful for risk stratification and care planning. We 
support a call for urgent work in this area. 
 
Outpatient Care Delivery; Potential for Remote/ Digital Tools 
1. Consultations 
In compliance with the ‘stay at home’ mandate, most structured education and non-
urgent routine care has been cancelled or is being delivered where necessary through 
remote consultation.  Remote consultations may take longer than face to face, but rates 
of “nonattendance” may be lower, and patient satisfaction can be high (23). On-line 
prescribing, reordering, dispensing and delivery should be encouraged. 
 
2. Education  
Patient self-management is key to good diabetes outcomes, encompassing 
management of lifestyle, insulin dose titration, foot self-care, and adherence to 
treatment plans. Health care professional (HCP) support can be delivered using on-line 
tools or telephone, although many patients value the use of physical aids and peer 
support of face to face/ group sessions  Online structured education resources include: 
online DESMOND (https://www.desmond-project.org.uk), BERTIE (type 1 diabetes) 
(https://www.bertieonline.org.uk), and the MyDiabetesMyWay (MDMW)/ MyWay 
Digital  platform (https://mywaydigitalhealth.co.uk). Apps incorporating 1:1 digital 
coaching include; Oviva (https://oviva.com/uk/en/), Changing health 
(https://www.changinghealth.com), Our Path/ Second Nature 
(https://www.changinghealth.com), Liva (https://livahealthcare.com), Omada 
(https://www.omadahealth.com) and Livongo (https://www2.livongo.com). Some 
providers are offering discounted or free services during the pandemic.  Use of public 
information sites for COVID-19/ sick day rules are valued. The NHS Scotland 
MyDiabetesMyWay COVID-19/ sick day advice page had 13,443 views with 98% positive 
ratings/ comments (n=368) over 3 weeks since 16th March.  Digitally supported diabetes 
self-management has the potential to be effective (24) and could be cost saving (25). 
Whether uptake increases during the pandemic period, preventing care deterioration, 
remains to be seen (26). 
 
3. Remote Monitoring 
a. Glucose Monitoring. Remote upload of home glucose recordings enabling 
remote health care professional review and feedback, is possible through proprietary 
systems such as LibreView, CareLink, Clarity, glucose data aggregator systems such 
as Diasend and Tidepool, and other independent applications. Pre-COVID-19, the 
number of ‘at home’ glucose uploads versus ‘in-clinic’ uploads was limited. Early NHS 
Scotland data (unpublished) suggests a steady (7%) increase in home LibreView 
uploads during last 4 weeks.  Patients with gestational diabetes (GDM) attend 
hospital approximately fortnightly during later pregnancy. Glucose data feedback 
could be facilitated remotely using technology including specific systems e.g. 
Sensyne Health’s GDM-Health app (https://www.sensynehealth.com/gdm-health). 
b. Activity, physiological parameters and  ‘Internet of things’ monitoring. 
Many apps/ online platforms enable sharing of home activity, blood pressure,  
weight and other readings with health care teams, either through automatic/ 
bluetooth connectivity or manual data entry (e.g. https://mwdh.co.uk, 
https://mymhealth.com). These could support ongoing lifestyle change and enable 
treatment optimisation. 
c. Biochemical Blood and Urine Testing. Nationally recommended blood and 
urine screening (13) may need deferred. Remote consultation without recent HbA1c 
results is challenging, particularly if no home glucose data is available. Products 
enabling HbA1c home testing (27,28), and systems using smart phone embedded 
technology enabling ‘at home’ diagnostics (e.g. DipiO ; https://healthy.io / Testcard; 
https://testcard.com for urine Albumin Creatinine Ratio), could help, but none have 
been widely implemented to date.  
d. Foot Care. Remote solutions to support neuro-vascular assessment, 
preventative podiatry work and active foot disease treatments are limited but simple 
at home neuropathy tests such as the ‘Ipswich touch the toes test’ may be 
sufficiently reliable when performed by a relative or carer (29) and home foot 
pressure mats/ remote neuropathy detection systems could assist where available 
(30). Home upload of digital photographs with or without additional wound tracking 
applications (e.g. https://healthy.io/wound) may reduce attendance episodes for 
ulcer treatment. 
e. Eye Screening. Currently, eye screening is widely facilitated through 
industrial screening cameras in clinical centres linked to systematic image review 
with or without artificial intelligence grading (31). Smart phones have been used as 
retinal cameras, but the technology does not yet enable individual home ownership, 
and is currently largely utilised through community hubs, e.g. in rural India (32). 
As routine complication screening declines, a deterioration in outcomes is predicted. 
Whether remote solutions can be rapidly implemented to plug the gap remains to be seen. 
Diabetes screening, monitoring and education will ultimately be deliverable from the home, 
through standard personal mobile devices. The main barriers will be changing healthcare 
organisation, procurement/ reimbursement practices, and supporting end users. Whilst 80% 
of UK adults own smartphones (33) and 95 % of 16-74 year olds in UK access the internet 
regularly (34), the majority of people with type 2 diabetes are over age 65 (35, 36) and some 
may lack skills to independently use digital tools. Technology user support in healthcare is 
distinctly under-resourced, and changes in service delivery during this stage of the 
pandemic may increase health inequalities.   There are also concerns that mental health 
may deteriorate due to stress and social isolation.  Online tools and telephone support may 
require signposting for high risk individuals. 
 
Innovation and Procurement/ Commissioning  
The COVID-19 pandemic has enforced a period of disruptive innovation.  As a result, 
information governance barriers are crumbling and procurement rules are being rewritten. 
One NHS trust, saw an 18 -month planned Microsoft Teams implementation happen over a 
weekend, and a 20-year rule disallowing health care professional-patient email contact 
changed overnight.  In the USA, reimbursement barriers for telemedicine services are 
rapidly evaporating. A reform of procurement procedures has enabled rapid commissioning 
and deployment of services and systems. The first wave has rightly focused on solutions 
with immediate impact, such as COVID-19 testing kits, vaccine development, hand wash, 
and ventilators, but attention may turn to tools supporting chronic conditions management 
if social distancing measures continue. 
Diabetes Opportunities Resulting from COVID-19 Restrictions 
may include: 
 The use of technology/ remote consultations may increase in the long term, meaning 
more flexible care delivery accommodating patient lifestyle, work and carer 
commitments (with secondary environmental (less travel), and economic (less time off 
work) benefits (37)), replacing rigidly timed protocolised face-to-face appointments. 
Care delivery may also better support acute needs; including proactive delivery of sick 
day guidance.  
 Rigid reliance on standard guidelines for populations may give way to more 
individualised patient- centred care. Risk stratification may increasing become part of 
service delivery, with proportionately more time focusing and re-engaging those at 
highest risk of deterioration including disengaged populations. This could transform 
care outcomes and cost of delivery; currently a small percentage of high-risk diabetes 
patients consume disproportionate costs due to treatment of complications (38, 39).  
 Efficiency in care delivery could improve through continuation of COVID-19 clinic 
service and personnel restructuring.  
Conclusions 
 
The COVID-19 pandemic has requiring rapid adaptation of care delivery, supported by 
governmental and national body recommendations, but has created a conflict around 
where care priorities should lie. Whether similar systematic change is possible in less 
developed, lower resourced countries remains to be seen. People with diabetes could suffer 
disproportionately during COVID-19. Service restructuring and digital tools may reduce risks 
of health decline during this period. Whilst the current focus is on limiting the terrible harm 
caused by the pandemic, it is possible that COVID-19 might leave a legacy of accelerated 
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Figure 1 represents a consensus document to support the management of inpatient diabetes 
during COVID-19 based on practice from a number of UK centre. Included with permission 
from lead authors  
 
Figure 2: 
Figure 2 represents a consensus flow chart produced by the NHS London Clinical Network for 
Outpatient Appointment Prioritisation for Specialist Diabetes Departments during the 
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